Overview

To Evaluate the Safety and Efficacy of Ipatasertib (GDC-0068) in Combination With Paclitaxel in Platinum-resistant Recurrent Epithelial Ovarian Cancer

Status:
Withdrawn

Trial end date:
2023-10-01

Target enrollment:

Participant gender:

Summary

This is a phase II open label, non-randomized, study to evaluate the safety and efficacy of Ipatasertib (GDC-0068) in combination with paclitaxel in platinum-resistant recurrent epithelial ovarian cancer.

Phase:

Phase 2

Details

Lead Sponsor:

Icahn School of Medicine at Mount Sinai

Treatments:

Paclitaxel